CBD Oil And Lamotrigine

CBDISTILLERY

Buy CBD Oil Online

Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain This is an open access article distributed under the Creative Commons Attribution License, My son had one seizure at 17 years old. He has not been diagnosed with epilepsy, but he did have an abnormal EEG that showed "slowing" so he was put on meds. After a few months on Keppra he became very depressed and moody. We changed to Lamotrigine, and although he has been seizure free for 2+ years now, he is increasingly depressed, irritable, has mood swings, and his grades Drug Interaction With Cbd Oil A Lamotrigine Cbd User Guide – Global Clubfoot Initiative Nanotechnology Cbd cbd places by me, drug interaction with cbd oil a lamotrigine Cbd Pain Relief Zebra Cbd

Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Choosing an appropriate treatment for chronic pain remains problematic, and despite the available medication for its treatment, still, many patients complain about pain and appeal to the use of cannabis derivatives for pain control. However, few data have been provided to clinicians about the pharmacokinetic drug-drug interactions of cannabinoids with other concomitant administered medications. Therefore, the aim of this brief review is to assess the interactions between cannabinoids and pain medication through drug transporters (ATP-binding cassette superfamily members) and/or metabolizing enzymes (cytochromes P450 and glucuronyl transferases).

1. Introduction

A drug-drug interaction (DDI) occurs when one drug alters the clinical effect of another. Drug interactions occur on pharmacodynamic and pharmacokinetic levels. In the first case, one drug may alter the sensitivity or responsiveness to another drug. Pharmacokinetic DDIs occur when a drug alters the absorption or disposition (distribution and elimination) of a concomitantly administered drug. This change can lead to an altered quantity of drug at the site of action affecting the magnitude and duration of the effect. In this scenario, a drug is a perpetrator referring to the one that causes an effect on the substrate drug, for example, by inducing or inhibiting drug-metabolizing enzymes. Although DDIs are often associated with toxicity or therapeutic failure [1], sometimes they can produce beneficial effects to the patient (i.e., improving the bioavailability of a drug and producing additive or synergistic effects) [2]. In any case, clinicians must be familiar with DDIs in order to improve prescribing tools.

During the last 5 years, a dramatic rise in the use of cannabis led to an increased number of patients taking it simultaneously with their previous medication. This situation could result in several problems as cannabinoids may be classified as either perpetrators or substrates depending on the concomitant drugs leading to altered exposure, adverse events, and/or lack of clinical efficacy. However, scarce evidence is available about cannabis drug interactions with potential implications in clinical efficacy and safety.

The endocannabinoid system has been recognized as a potential therapeutic target. Either highly purified cannabidiol (such as Epidiolex recently approved in the United States for use in Lennox–Gastaut or Dravet syndrome) or formulations with different Δ 9 -tetrahydrocannabinol (THC) to cannabidiol (CBD) ratios (such as Sativex, an oromucosal spray for the treatment of multiple sclerosis-associated spasticity) are being investigated for other disease states. Although the use of cannabinoids for the treatment of pain is supported by some controlled clinical trials [3–5], currently and according to systematic reviews and meta-analysis [6–8], there is only moderate evidence to support the use of cannabinoids in treating chronic pain and larger and higher quality clinical trials are needed. Despite this fact, chronic pain relief is by far the most common condition cited by patients using cannabis for medical purposes and very little is known about potential pharmacokinetic interactions with common medication prescribed for chronic pain.

Nowadays, even cannabinol (CBN), a byproduct of THC degradation, is being studied for its analgesic effect [9].

CBD, THC, and CBN are extensively metabolized in the liver and in the intestine. Mainly CYP2C19 and, to a lesser extent, CYP3A4 are implicated in CBD biotransformation [10, 11]. CBD can also undergo direct conjugations via UDP-glucuronosyltransferase (UGT) enzymes, such as UGT1A9, UGT2B7, and UGT2B17 [12, 13]. THC biotransformation is primarily dependent on CYP2C9 and CYP3A4 isoenzymes [14], but UGT enzymes play a critical role in metabolizing THC metabolites (THC-OH, THC-COOH) as well [12]. CBN is metabolized by CYP2C9 and CYP3A4 and can also undergo direct glucuronidation by hepatic UGT1A9 and the extrahepatic UGT1A7, UGT1A8, and UGT1A10 [12, 14].

CBD is not only a substrate but also an inhibitor of CYP450 enzymes and UGTs. In addition, some isoenzymes of the cytochrome P450 system or UGTs are also subjected to inhibition by THC and CBN [11, 15–25].

Regarding the inducing activity of cannabinoids, smoked cannabis may increase the clearance of drugs metabolized by CYP1A2 [24, 25], resulting in lower concentrations of these drugs and perhaps in therapeutic failure.

Furthermore, in vitro and animal studies have shown that CBD, THC, and CBN interact in some way with ATP-binding cassette superfamily: breast cancer-resistant protein (Bcrp) and glycoprotein P (Pgp). Thus, a significant impact on the absorption and disposition of other coadministered drugs that are also substrates of these transporters may be expected. According to some preclinical studies [26–29], CBD inhibits Pgp and Bcrp. Even though inhibitors are often substrates, different in vitro and animal studies show that CBD is not a Pgp substrate [30, 31] and it acts provoking a downregulation in Pgp expression. THC and CBN could also deregulate Pgp, Bcrp, and multidrug-resistant protein (MRP) 1-4 expression [15]. An overview of the effect of cannabinoids on CYP450 isoenzymes, UGTs, and efflux transporters is summarized in Table 1 .

Table 1

Effect of cannabinoids on CYP450 isoenzymes, UGTs, and efflux transporters.

Cannabinoids CYP P450 isoenzymes UGTs Modulation of efflux transporter expression
CBD Inhibition of CYP1A1, CYP1A2, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and CYP2D6 Inhibition of UGT1A9 and 2B7 Deregulation of Pgp, BCRP, and MRP1-4 transporter expression
THC Inhibition of CYP3A4, CYP2D6, and CYP2C9 THC-OH, THC-COOH (metabolites) can compete with glucuronidation pathways
CBN Inhibition of CYP3A4, CYP2D6, and CYP2C9 Inhibition of UGT1A7, 1A8, and 1A9

BCRP: breast cancer resistance proteins; CBD: cannabidiol; CBN: cannabinol; CYP: cytochrome; MRP: multidrug resistance proteins; Pgp: glycoprotein P; THC: Δ 9 -tetrahydrocannabinol; THC-OH: 11-hydroxy-tetrahydrocannabinol; THC-COOH: 11-nor-9-carboxy-tetrahydrocannabinol; UGTs: UDP glucuronosyltransferases.

As cannabinoids are often used as add-on therapy, the occurrence of DDIs seems more plausible. Therefore, their use in the therapy could interfere with the disposition of other drugs that undergo the same metabolic pathways. Nonetheless, few studies in humans have been carried out and reported in the literature about DDIs of cannabinoids with other prescribed medications [32–34] and some of them are only case reports [35–37].

Although in vitro or animal studies about DDIs should not be extrapolated to human beings, healthcare providers should be aware of clinically important DDIs leading in some cases to therapeutic improvement or in other cases to therapeutic failure or toxicity. Therefore, this review addresses a comprehensive overview of potential pharmacokinetic interactions affecting drug metabolism enzymes such as cytochrome P450 or UGTs and membrane efflux transporters between cannabinoids and drugs used for chronic pain.

2. Methodology

Electronic databases of published scientific literature were the main source for this review. The in vitro and in vivo research findings and clinical case reports were searched from PubMed, Google Scholar, and Cochrane Library. Some studies were identified with Google search. Additional articles of interest were obtained through cross-referencing of published literature. The primary key terms used were “pharmacokinetics,” “drug interactions,” “cannabinoids,” “metabolizing enzymes,” “efflux transporters,” and “chronic pain medication.” Only English language papers were taken into consideration.

3. Drug-Drug Interactions

3.1. Cannabinoids-Opioids

The conventional opioids most commonly used for chronic pain management are morphine, oxycodone, codeine, methadone, tramadol, and fentanyl. Most opioids exert an analgesic effect through binding to the μ opioid receptor except for tramadol and methadone that include both opioid and nonopioid components [38, 39].

Morphine is glucuronidated via UGT2B7 to morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), being the latter a highly active analgesic [40].

Oxycodone is metabolized in the liver by CYP3A4/5 and CYP2D6. An active metabolite (oxymorphone) is formed by CYP2D6 [41, 42]. Oxycodone glucuronidation is carried out by UGT2B7 and UGT2B4 while oxymorphone is glucuronidated mostly by UGT2B7 [43].

CBD inhibits UGT2B7, and thus, a lower M6G to morphine ratio should be expected and less analgesic potency. Moreover, CBD, THC, and CBN inhibit CYP2D6 affecting oxymorphone formation and thus reducing analgesic effect. Therefore, if the interactions mentioned above take place, perhaps less analgesia would be seen with the combination of cannabis and these two opioids. However, several studies in the literature report that cannabis enhances the analgesic effects of opioids, thereby allowing for lower doses [44–47]. Furthermore, Abrams et al. [48] found that vaporized cannabis given to patients with chronic pain on opioid therapy (morphine or oxycodone) increased the analgesic effect of opioids but no significant differences were observed in the mean plasma concentration-time curves for morphine and oxycodone with and without cannabis treatment. These authors suggested pharmacodynamic interactions between opioids and cannabinoids. However, as opioid delivery to the brain is influenced by ATP-binding cassette transporters [49–51], a pharmacokinetic interaction should not be neglected.

Several cytochrome P450 enzymes are involved in methadone metabolism: CYP3A4, CYP2B6, and CYP2C19 and, to a lesser extent, CYP2C9, CYP2C8, and CYP2D6. It has become clear nowadays that CYP2B6, rather than CYP3A4, is the predominant P450 responsible for clinical methadone disposition [52]. CBD is a strong inhibitor of CYP2B6, so increased levels of this opioid and a greater analgesic potency might be observed. An increased plasma level of methadone was observed in a pediatric patient receiving CBD [36], which decreased fourteen days after CBD was discontinued.

Some authors [53] concluded that morphine and methadone analgesia was greater in mice lacking Pgp. Hassan et al. [54] found that oxycodone is a Pgp substrate in vivo. Some studies [50, 55, 56] suggested that this efflux transporter limits the entry of some opiates into the brain and that administration of Pgp inhibitors or drugs that downregulate Pgp expression can increase the sensitivity to these opiates. This fact, rather than enzyme inhibition by cannabinoids, could be the explanation of augmented analgesic potency of opiates, and the need of lowering their doses in the presence of cannabinoids as efflux transporters are deregulated by cannabinoids. This could be the case for morphine, oxycodone, and methadone as they are substrates of efflux transporters.

Neither codeine nor tramadol is Pgp substrates [51, 57]. The polymorphic CYP2D6 regulates the O-demethylation of codeine and tramadol to more potent metabolites: morphine and O-desmethyl-tramadol, respectively. Tramadol undergoes another metabolic pathway catalyzed by CYP3A4 and CYP2B6.

According to some authors [58], if the subject is a poor metabolizer, inadequate analgesia can be observed. If CBD, THC, or CBN inhibition of CYP2D6 predominates, the analgesic effects of tramadol and codeine will be reduced. However, the fate of the active metabolites has to be taken into account as well. O-desmethyl-tramadol undergoes inactivation by UGT2B7 and UGT1A8 [59], and morphine as stated before is a Pgp substrate. If cannabinoids interfere in the elimination of these metabolites either by inhibiting UGT2B7 or by deregulating efflux transporter expression, the result will be the opposite. Further studies are necessary in order to assess cannabinoid influence on codeine and tramadol.

Fentanyl is mainly metabolized by CYP3A4 and is a Pgp substrate [50, 60]. Although some authors found no interaction between fentanyl given intravenously and CBD [61], plasma levels of fentanyl were undetectable before and after the administration of CBD. Therefore, deeper research is necessary in order to conclude on a possible pharmacokinetic interaction.

To sum up, if opioids and/or their active metabolite levels are increased when taken along with cannabinoids, an enhanced analgesic activity can be observed.

3.2. Cannabinoids-Acetaminophen

Acetaminophen (paracetamol) is a drug with analgesic and antipyretic properties widely used for pain relief. Although its analgesic effect is weaker in comparison with nonsteroidal anti-inflammatory drugs (NSAIDs), it can be considered as a first-line option among nonopioids due to a more favorable safety profile. However, high concentrations can induce liver damage, and therefore, daily doses should not exceed 4 g [62].

Acetaminophen glucuronidation by UGT1A1, UGT1A6, UGT1A9, and UGT2B15 is the main biotransformation pathway, and only a minor fraction of the drug is oxidized to the highly reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) [63]. Acetaminophen-induced liver toxicity with the concomitant use of phenytoin or phenobarbital or with the use of tyrosine kinase inhibitors was reported in the literature [64, 65]. The interaction is assumed to be due to competition or inhibition of UGT activities. A recent study [66] revealed that the coadministration of a cannabidiol-rich cannabis extract and acetaminophen results in alterations in the livers of aged female mice. As cannabinoids can inhibit UGTs, a higher concentration of acetaminophen might be expected. When glucuronidation is compromised, acetaminophen is directed towards the formation of the reactive metabolite NAPQI resulting in liver damage.

Moreover, acetaminophen is a MRP2 substrate so deregulation of this transporter by the concomitant use of cannabinoids can result in higher levels of the drug as well [67].

3.3. Cannabinoids-Antidepressants

Mixed-action antidepressants (serotonin and norepinephrine-reuptake inhibitors) such as duloxetine, amitriptyline, and venlafaxine are a mainstay in the treatment of many chronic pain conditions [68].

Elimination of duloxetine is mainly through hepatic metabolism involving CYP1A2 and to a lesser extent CYP2D6. There is evidence that coadministration of duloxetine with CYP1A2 and CYP2D6 inhibitors increased duloxetine levels [69]. As stated before, CBD is an inhibitor of CYP1A2 and THC, CBD, and CBN inhibit CYP2D6, so if cannabinoids are used as a concomitant medication, an increase in duloxetine plasma levels may be seen.

Venlafaxine relies on CYP2D6 for conversion to O-desmethylvenlafaxine (major active metabolite). Further conversion of this metabolite involves CYP2C19 and CYP3A4. Venlafaxine is also metabolized by CYP2C19, CYP2C9, and CYP3A4 but to a lesser extent [70]. As all the enzymes implied in venlafaxine and its active metabolite biotransformation are inhibited by cannabinoids, the clinical implication is difficult to predict. Several studies evaluating CYP2D6 polymorphism [71–73] concluded that higher venlafaxine and lower O-desmethylvenlafaxine levels in poor metabolizers resulted in a reduced clinical response with an increased risk for side effects in comparison with extensive metabolizers. Polymorphisms in the CYP2C19 genes that result in decreased enzymatic activity have also been documented [74, 75]. Therefore, elevated venlafaxine levels caused by the potential inhibition of cannabinoids of its metabolic pathway can affect drug response and its side-effect profile.

Amitriptyline is metabolized mostly by CYP2D6, CYP3A4, and CYP2C19, the latter leading to the formation of nortriptyline (active metabolite). Other isozymes involved in amitriptyline metabolism are CYP1A2 and CYP2C9. Based on dosing recommendations made by the Clinical Pharmacogenetics Implementation Consortium in 2016 according to CYP2D6 and/or CYP2C19 variants of individuals [76], if the level of amitriptyline and its active metabolites are too high as happening in poor metabolizers, there is an increased risk of toxicity. Certain drugs as cannabinoids inhibit the activity of these isoenzymes and make normal metabolizers resemble poor metabolizers.

Regarding efflux transporters in the brain, recent studies supported a low possibility that Pgp affects these drugs [77].

To sum up, drug interactions between cannabinoids and antidepressants, if they occur, may be due to metabolizing enzyme inhibition. This inhibition may increase the levels of the antidepressants or their active metabolites resulting in side effects such as the serotonin syndrome, hyponatraemia [78–80], hemorrhagic events [81–84], and QT interval prolongation among others [85, 86]. In the case of duloxetine and amitriptyline, as both drugs are metabolized by CYP1A2, chronic smoked cannabis use may result in lower concentrations of these drugs and perhaps lower efficacy.

3.4. Cannabinoids-Anticonvulsants

Antiepileptic drugs are used worldwide to treat several disorders other than epilepsy, such as neuropathic pain, migraine, and bipolar disorder [87]. The first-line options for the treatment of various neuropathic pain conditions are carbamazepine, gabapentin, and pregabalin [88].

Pregabalin and gabapentin share a similar mechanism of action, and both undergo renal excretion [89]. Based on the renal elimination of these drugs, no DDIs between these gabapentinoids and cannabinoids should be expected. With regard to efflux transporters, some authors’ results [90] suggested that a combined treatment of pregabalin with Pgp inhibitors enables the prolongation of dose interval of this drug. However, no studies in literature found increased pregabalin levels in the brain with the use of Pgp inhibitors.

Although Gaston et al. [32] did not find changes in carbamazepine levels when administered with cannabis, they focused the study on CBD as the perpetrator drug and carbamazepine as the substrate but information is lacking about the influence of concomitant carbamazepine on CBD plasma levels. Carbamazepine is a well-known inducer of CYP3A4 [91], and therefore, THC, CBD, and CBN metabolism could be affected leading to lower plasma concentrations of these cannabinoids.

Although there is insufficient evidence to support the use of valproic acid for neuropathic pain and fibromyalgia [92], it is sometimes used for these purposes in the clinical practice. Valproic acid is metabolized by three different routes: glucuronidation (UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15) and β-oxidation (using carnitine as a carrier) in the mitochondria (major pathways) and a minor route (ω-oxidation) leading the latter to the formation of a hepatotoxic metabolite (4-en-VPA) [93, 94]. According to some studies [95], valproic acid inhibited UGT1A9 in an uncompetitive manner and UGT2B7 competitively. Glucuronidation is also involved in CBD metabolism being CBD an inhibitor of UGT1A9 and UGT2B7. On the one hand, if cannabinoid concentrations are high, perhaps CBD may impair valproic acid glucuronidation, and thus, valproic acid clearance may be reduced. The higher concentrations of valproic acid induce carnitine depletion [96], and this could increase the ω-oxidation route leading to a higher concentration of 4-en-VPA (hepatotoxic metabolite). This last fact could result in incorrect ammonium elimination and thus hyperammonemia [97–99]. On the other hand, valproic acid inhibits UGT1A9 and UGT2B7, both involved in cannabinoid elimination. Perhaps, this inhibition plays the main role and higher concentrations of cannabinoids could be seen in turn. This fact could be supported by the observation made by Gaston et al. [32]. Although these researchers did not measure CBD levels, they did not find a significant change in the valproate levels with increasing doses of CBD but a rise in aspartate transaminase (AST) and/or alanine transaminase (ALT) levels after CBD treatment. These authors concluded that CBD enhances the negative effects of valproic acid on liver functions, but perhaps, valproic acid is the one that intensifies CBD hepatotoxicity augmenting its blood levels. Research done in mice [100] showed that CBD treatment increases liver-to-body weight, ALT, AST, and total bilirubin. In clinical trials carried out recently, some authors [101–103] found elevated liver enzymes in 5-20% of patients treated with CBD, and some patients had to be withdrawn from the studies due to serious hepatic complications. So the combination of CBD with other drugs that exhibit hepatotoxicity and interact with CBD should be of great concern. Valproic acid is not a substrate of Pgp or MRPs [104], so interactions with cannabinoids at this level are unlikely.

Regarding lamotrigine, although the evidence of its efficacy in chronic pain is unconvincing, it can have some effect in patients with painful HIV-related neuropathy [105] and in the prevention of migraine with aura [106]. Lamotrigine is predominantly metabolized by glucuronidation (UGT1A4 and UGT2B7), and it also undergoes elimination by a minor elimination pathway that involves CYP450 enzymes [107]. This minor route converts the drug to a reactive arene oxide metabolite [108]. Such intermediate metabolite, if not effectively detoxified, can result in cellular damage [109]. Skin injuries, Stevens-Johnson syndrome, and toxic epidermal necrolysis are all reported adverse events related to lamotrigine use [110], mainly when the drug is coadministered with valproic acid [111–113], a well-known inhibitor of the glucuronidation pathway. Cannabinoids can act inhibiting UGTs [114] in the same way valproic acid does. So, in the absence of the major pathway, lamotrigine can be bioactivated to the arene oxide and an increased risk of skin reactions in patients could be expected. In addition, lamotrigine is a substrate of Pgp and BCRP [115], so downregulation of their expression provoked by cannabinoids can intensify the drug effect.

See also  CBD Oil Half Life

A comprehensive overview of the potential interactions discussed in the text is summarized in Table 2 .

Table 2

Drugs commonly used in chronic pain, their main metabolic pathways, efflux transporter implication, and the result of potential interaction with cannabinoids.

Drugs Efflux transporter substrate Metabolic pathway Potential cannabinoid interaction
Morphine Yes UGT2B7 Augmented analgesic potency due to efflux transporters downregulation. Dose reduction may be required.
Codeine No CYP2D6 Possible augmented analgesia provoked by the active metabolite (morphine) by downregulation of efflux transporter expression. Dose reduction may be required.
Oxycodone Yes CYP3A4/5, CYP2D6, UGT2B7, and UGT2B4 Augmented analgesia due to parent drug or active metabolite by efflux transporter downregulation and/or enzyme inhibition. Dose reduction may be required.
Methadone Yes CYP3A4, CYP2B6, CYP2C19, CYP2C9, CYP2C8, and CYP2D6 Augmented analgesia due to enzyme inhibition and/or efflux transporter downregulation. Dose reduction may be required.
Tramadol No CYP2D6, CYP2B6, and CYP3A Possible augmented analgesia due to inhibition of metabolism of active metabolite. Dose reduction may be required.
Fentanyl Yes CYP3A4 Possible augmented analgesia due to inhibition of metabolism and/or efflux transporter downregulation.
Acetaminophen Yes UGT1A1, UGT1A6, UGT1A9, and UGT2B15 Higher levels of acetaminophen due to UGT inhibition and/or efflux transporter downregulation and thus possible hepatotoxicity. Monitor adverse effects.
Duloxetine No CYP1A2, CYP2D6 Higher concentration of antidepressant due to metabolizing enzyme inhibition. Dose reduction may be required.
Smoked cannabis may increase clearance of duloxetine. Monitor for loss of efficacy with chronic marijuana use.
Venlafaxine No CYP2D6, CYP2C19, CYP2C9, and CYP3A4 Higher concentration of antidepressant due to metabolizing enzyme inhibition. Dose reduction may be required.
Amitriptyline No CYP2D6, CYP3A4, CYP2C19, CYP1A2, and CYP2C9 Higher concentration of parent drug and/or active metabolites due to metabolizing enzyme inhibition. Dose reduction may be required.
Smoked cannabis may increase clearance of amitriptyline. Monitor for loss of efficacy with chronic marijuana use.
Valproic acid No UGT1A3, A4, A6, A8, A9, A10, UGT2B7, UGT2B15, and β-oxidation in the mitochondria (using carnitine as carrier) Possible higher levels of valproic acid by inhibition of UGTs or higher levels of cannabinoids due to valproic acid UGT inhibition. In both cases, the interaction could result in hepatic damage. Monitor adverse effects.
Lamotrigine Yes UGT1A4, UGT2B7 Higher levels of lamotrigine by UGT inhibition and/or downregulation of efflux transporters. Possible cutaneous reactions. Dose reduction may be required.

4. Conclusion

Data on significant DDIs between cannabinoids and other medications is still limited and most of it comes from in vitro and animal studies. The results obtained in the literature may be of help, but they cannot be extrapolated to human beings. Given that the widespread use of cannabinoids will certainly continue, further research in humans is essential to clarify DDIs in order to fully understand their relevance in the clinical setting.

Conflicts of Interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

1. Abubakar A. R., Chedi B. A. Z., Mohammed K. G., Haque M. Drug interaction and its implication in clinical practice and personalized medicine. National Journal of Physiology, Pharmacy and Pharmacology. 2015; 5 (5):343–349. doi: 10.5455/njppp.2015.5.2005201557. [CrossRef] [Google Scholar]

2. Gerber W., Steyn J. D., Kotzé A. F., Hamman J. H. Beneficial pharmacokinetic drug interactions: a tool to improve the bioavailability of poorly permeable drugs. Pharmaceutics. 2018; 10 (3):p. 106. doi: 10.3390/pharmaceutics10030106. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Andreae M. H., Carter G. M., Shaparin N., et al. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. The Journal of Pain. 2015; 16 (12):1221–1232. doi: 10.1016/j.jpain.2015.07.009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Vučković S., Srebro D., Vujović K. S., Vučetić Č., Prostran M. Cannabinoids and pain: new insights from old molecules. Frontiers in Pharmacology. 2018; 9, article 1259 doi: 10.3389/fphar.2018.01259. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

5. Whiting P. F., Wolff R. F., Deshpande S., et al. Cannabinoids for medical use: a systematic review and meta-analysis. Journal of the American Medical Association. 2015; 313 (24):2456–2473. doi: 10.1001/jama.2015.6358. [PubMed] [CrossRef] [Google Scholar]

6. Johal H., Devji T., Chang Y., Simone J., Vannabouathong C., Bhandari M. Cannabinoids in chronic non-cancer pain: a systematic review and meta-analysis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2020; 13 :13. doi: 10.1177/1179544120906461. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

7. Cameron E. C., Hemingway S. L. Cannabinoids for fibromyalgia pain: a critical review of recent studies (2015–2019) Journal of Cannabis Research. 2020; 2 (1, article 19) doi: 10.1186/s42238-020-00024-2. [CrossRef] [Google Scholar]

8. Mücke M., Phillips T., Radbruch L., Petzke F., Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2018; 3 (3) doi: 10.1002/14651858.cd012182.pub2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

9. Wong H., Cairns B. E. Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. Archives of Oral Biology. 2019; 104 :33–39. doi: 10.1016/j.archoralbio.2019.05.028. [PubMed] [CrossRef] [Google Scholar]

10. Jiang R., Yamaori S., Takeda S., Yamamoto I., Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sciences. 2011; 89 (5-6):165–170. doi: 10.1016/j.lfs.2011.05.018. [PubMed] [CrossRef] [Google Scholar]

11. Zendulka O., Dovrtělová G., Nosková K., et al. Cannabinoids and cytochrome P450 interactions. Current Drug Metabolism. 2016; 17 (3):206–226. doi: 10.2174/1389200217666151210142051. [PubMed] [CrossRef] [Google Scholar]

12. Mazur A., Lichti C. F., Prather P. L., et al. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metabolism and Disposition. 2009; 37 (7):1496–1504. doi: 10.1124/dmd.109.026898. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Ujváry I., Hanuš L. Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis and Cannabinoid Research. 2016; 1 (1):90–101. doi: 10.1089/can.2015.0012. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Watanabe K., Yamaori S., Funahashi T., Kimura T., Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sciences. 2007; 80 (15):1415–1419. doi: 10.1016/j.lfs.2006.12.032. [PubMed] [CrossRef] [Google Scholar]

15. Alsherbiny M. A., Li C. G. Medicinal cannabis-potential drug interactions. Medicines. 2019; 6 (1):p. 3. doi: 10.3390/medicines6010003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Arellano A. L., Papaseit E., Romaguera A., Torrens M., Farre M. Neuropsychiatric and general interactions of natural and synthetic cannabinoids with drugs of abuse and medicines. CNS & Neurological Disorders Drug Targets. 2017; 16 (5):554–566. doi: 10.2174/1871527316666170413104516. [PubMed] [CrossRef] [Google Scholar]

17. Stout S. M., Cimino N. M. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metabolism Reviews. 2013; 46 (1):86–95. doi: 10.3109/03602532.2013.849268. [PubMed] [CrossRef] [Google Scholar]

18. Yamaori S., Ebisawa J., Okushima Y., Yamamoto I., Watanabe K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sciences. 2011; 88 (15-16):730–736. doi: 10.1016/j.lfs.2011.02.017. [PubMed] [CrossRef] [Google Scholar]

19. Yamaori S., Okamoto Y., Yamamoto I., Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metabolism and Disposition. 2011; 39 (11):2049–2056. doi: 10.1124/dmd.111.041384. [PubMed] [CrossRef] [Google Scholar]

20. Opitz B. J., Ostroff M. L., Whitman A. C. The potential clinical implications and importance of drug interactions between anticancer agents and cannabidiol in patients with cancer. Journal of Pharmacy Practice. 2020; 33 (4):506–512. doi: 10.1177/0897190019828920. [PubMed] [CrossRef] [Google Scholar]

21. Brown J. D., Winterstein A. G. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019; 8 (7):p. 989. doi: 10.3390/jcm8070989. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Qian Y., Gurley B. J., Markowitz J. S. The potential for pharmacokinetic interactions between cannabis products and conventional medications. Journal of Clinical Psychopharmacology. 2019; 39 (5):462–471. doi: 10.1097/JCP.0000000000001089. [PubMed] [CrossRef] [Google Scholar]

23. Rong C., Carmona N. E., Lee Y. L., et al. Drug-drug interactions as a result of co-administering Δ 9 -THC and CBD with other psychotropic agents. Expert Opinion on Drug Safety. 2017; 17 (1):51–54. doi: 10.1080/14740338.2017.1397128. [PubMed] [CrossRef] [Google Scholar]

24. Antoniou T., Bodkin J., Ho J. M. W. Drug interactions with cannabinoids. CMAJ. 2020; 192 (9, article E206) doi: 10.1503/cmaj.191097. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Kocis P. T., Vrana K. E. Delta-9-tetrahydrocannabinol and cannabidiol drug-drug interactions. Medical Cannabis and Cannabinoids. 2020:1–13. doi: 10.1159/000507998. [CrossRef] [Google Scholar]

26. Feinshtein V., Erez O., Ben-Zvi Z., et al. Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study. American Journal of Obstetrics and Gynecology. 2013; 209 (6):573.e1–573.e15. doi: 10.1016/j.ajog.2013.08.005. [PubMed] [CrossRef] [Google Scholar]

27. Holland M. L., Lau D. T. T., Allen J. D., Arnold J. C. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. British Journal of Pharmacology. 2007; 152 (5):815–824. doi: 10.1038/sj.bjp.0707467. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

28. Holland M. L., Panetta J. A., Hoskins J. M., et al. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochemical Pharmacology. 2006; 71 (8):1146–1154. doi: 10.1016/j.bcp.2005.12.033. [PubMed] [CrossRef] [Google Scholar]

29. Zhu H. J., Wang J. S., Markowitz J. S., et al. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. The Journal of Pharmacology and Experimental Therapeutics. 2006; 317 (2):850–857. doi: 10.1124/jpet.105.098541. [PubMed] [CrossRef] [Google Scholar]

30. Brzozowska N., Li K. M., Wang X. S., et al. ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. PeerJ. 2016; 4, article e2081 doi: 10.7717/peerj.2081. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. Feinshtein V., Erez O., Ben-Zvi Z., et al. Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines. PeerJ. 2013; 1, article e153 doi: 10.7717/peerj.153. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

32. Gaston T. E., Bebin E. M., Cutter G. R., Liu Y., Szaflarski J. P., the UAB CBD Program Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017; 58 (9):1586–1592. doi: 10.1111/epi.13852. [PubMed] [CrossRef] [Google Scholar]

33. Geffrey A. L., Pollack S. F., Bruno P. L., Thiele E. A. Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015; 56 (8):1246–1251. doi: 10.1111/epi.13060. [PubMed] [CrossRef] [Google Scholar]

34. Morrison G., Crockett J., Blakey G., Sommerville K. A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clinical Pharmacology in Drug Development. 2019; 8 (8):1009–1031. doi: 10.1002/cpdd.665. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

35. Grayson L., Vines B., Nichol K., Szaflarski J. P. An interaction between warfarin and cannabidiol, a case report. Epilepsy & Behavior Case Reports. 2018; 9 :10–11. doi: 10.1016/j.ebcr.2017.10.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

36. Madden K., Tanco K., Bruera E. Clinically significant drug-drug interaction between methadone and cannabidiol. Pediatrics. 2020; 145 (6, article e20193256) doi: 10.1542/peds.2019-3256. [PubMed] [CrossRef] [Google Scholar]

37. Leino A. D., Emoto C., Fukuda T., Privitera M., Vinks A. A., Alloway R. R. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. American Journal of Transplantation. 2019; 19 (10):2944–2948. doi: 10.1111/ajt.15398. [PubMed] [CrossRef] [Google Scholar]

38. Raffa R. B., Friderichs E., Reimann W., Shank R. P., Codd E. E., Vaught J. L. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. The Journal of Pharmacology and Experimental Therapeutics. 1992; 260 (1):275–285. [PubMed] [Google Scholar]

39. Baldo B. A. Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Archives of Toxicology. 2018; 92 (8):2457–2473. doi: 10.1007/s00204-018-2244-6. [PubMed] [CrossRef] [Google Scholar]

40. Osborne R., Joel S., Trew D., Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clinical Pharmacology and Therapeutics. 1990; 47 (1):12–19. doi: 10.1038/clpt.1990.2. [PubMed] [CrossRef] [Google Scholar]

41. Lalovic B., Phillips B., Risler L. L., Howald W., Shen D. D. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metabolism and Disposition. 2004; 32 (4):447–454. doi: 10.1124/dmd.32.4.447. [PubMed] [CrossRef] [Google Scholar]

42. Lalovic B., Kharasch E., Hoffer C., Risler L., Liuchen L., Shen D. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clinical Pharmacology and Therapeutics. 2006; 79 (5):461–479. doi: 10.1016/j.clpt.2006.01.009. [PubMed] [CrossRef] [Google Scholar]

43. Coffman B. L., King C. D., Rios G. R., Tephly T. R. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268) Drug Metabolism and Disposition. 1998; 26 (1):73–77. [PubMed] [Google Scholar]

44. Degenhardt L., Lintzeris N., Campbell G., et al. Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. Drug and Alcohol Dependence. 2015; 147 :144–150. doi: 10.1016/j.drugalcdep.2014.11.031. [PubMed] [CrossRef] [Google Scholar]

45. Haroutounian S., Ratz Y., Ginosar Y., et al. The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain. The Clinical Journal of Pain. 2016; 32 (12):1036–1043. doi: 10.1097/AJP.0000000000000364. [PubMed] [CrossRef] [Google Scholar]

46. Reiman A., Welty M., Solomon P. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis and Cannabinoid Research. 2017; 2 (1):160–166. doi: 10.1089/can.2017.0012. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

47. Cooper Z. D., Bedi G., Ramesh D., Balter R., Comer S. D., Haney M. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018; 43 (10):2046–2055. doi: 10.1038/s41386-018-0011-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

48. Abrams D. I., Couey P., Shade S. B., Kelly M. E., Benowitz N. L. Cannabinoid-opioid interaction in chronic pain. Clinical Pharmacology and Therapeutics. 2011; 90 (6):844–851. doi: 10.1038/clpt.2011.188. [PubMed] [CrossRef] [Google Scholar]

49. Chaves C., Remiao F., Cisternino S., Decleves X. Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain. Current Neuropharmacology. 2017; 15 (8):1156–1173. doi: 10.2174/1570159X15666170504095823. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

50. Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance. Current Topics in Medicinal Chemistry. 2011; 11 (9):1157–1164. doi: 10.2174/156802611795371288. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

51. Yang J., Reilly B., Davis T., Ronaldson P. Modulation of opioid transport at the blood-brain barrier by altered ATP-binding cassette (ABC) transporter expression and activity. Pharmaceutics. 2018; 10 (4):p. 192. doi: 10.3390/pharmaceutics10040192. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

52. Gadel S., Friedel C., Kharasch E. D. Differences in methadone metabolism by CYP2B6 variants. Drug Metabolism and Disposition. 2015; 43 (7):994–1001. doi: 10.1124/dmd.115.064352. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

53. Thompson S. J., Koszdin K., Bernards C. M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 2000; 92 (5):1392–1399. doi: 10.1097/00000542-200005000-00030. [PubMed] [CrossRef] [Google Scholar]

54. Hassan H. E., Myers A. L., Lee I. J., Coop A., Eddington N. D. Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel’s tissue distribution in Sprague Dawley rats. Journal of Pharmaceutical Sciences. 2007; 96 (9):2494–2506. doi: 10.1002/jps.20893. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

55. Rodriguez M., Ortega I., Soengas I., Suarez E., Lukas J. C., Calvo R. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. The Journal of Pharmacy and Pharmacology. 2004; 56 (3):367–374. doi: 10.1211/0022357022782. [PubMed] [CrossRef] [Google Scholar]

56. Wang J. S., Ruan Y., Taylor R. M., Donovan J. L., Markowitz J. S., DeVane C. L. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology. 2004; 173 (1-2):132–138. doi: 10.1007/s00213-003-1718-1. [PubMed] [CrossRef] [Google Scholar]

57. Kanaan M., Daali Y., Dayer P., Desmeules J. Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein. Basic & Clinical Pharmacology & Toxicology. 2009; 105 (3):199–206. doi: 10.1111/j.1742-7843.2009.00428.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

58. Kumar S., Kundra P., Ramsamy K., Surendiran A. Pharmacogenetics of opioids: a narrative review. Anaesthesia. 2019; 74 (11):1456–1470. doi: 10.1111/anae.14813. [PubMed] [CrossRef] [Google Scholar]

59. Gong L., Stamer U. M., Tzvetkov M. V., Altman R. B., Klein T. E. PharmGKB summary: tramadol pathway. Pharmacogenetics and Genomics. 2014; 24 (7):374–380. doi: 10.1097/FPC.0000000000000057. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

60. Smith H. S. Opioid metabolism. Mayo Clinic Proceedings. 2009; 84 (7):613–624. doi: 10.1016/S0025-6196(11)60750-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

61. Manini A. F., Yiannoulos G., Bergamaschi M. M., et al. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. Journal of Addiction Medicine. 2015; 9 (3):204–210. doi: 10.1097/ADM.0000000000000118. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

62. Jaeschke H. Acetaminophen: dose-dependent drug hepatotoxicity and acute liver failure in patients. Digestive Diseases. 2015; 33 (4):464–471. doi: 10.1159/000374090. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

63. Mazaleuskaya L. L., Sangkuhl K., Thorn C. F., FitzGerald G. A., Altman R. B., Klein T. E. PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenetics and Genomics. 2015; 25 (8):416–426. doi: 10.1097/FPC.0000000000000150. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

64. Kostrubsky S. E., Sinclair J. F., Strom S. C., et al. Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes. Toxicological Sciences. 2005; 87 (1):146–155. doi: 10.1093/toxsci/kfi211. [PubMed] [CrossRef] [Google Scholar]

65. Liu Y., Ramírez J., Ratain M. J. Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. British Journal of Clinical Pharmacology. 2011; 71 (6):917–920. doi: 10.1111/j.1365-2125.2011.03911.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

66. Ewing L. E., McGill M. R., Yee E. U., et al. Paradoxical patterns of sinusoidal obstruction syndrome-like liver injury in aged female CD-1 mice triggered by cannabidiol-rich cannabis extract and acetaminophen co-administration. Molecules. 2019; 24 (12):p. 2256. doi: 10.3390/molecules24122256. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

67. Hassany M., Hassanzadeh Khayat M., Behravan J., Kasaeeian J. Expression of drug pump protein MRP2 in lipopolysaccharide-treated rats and its impact on the disposition of acetaminophen. Iranian Journal of Pharmaceutical Research. 2011; 10 (4):855–859. [PMC free article] [PubMed] [Google Scholar]

68. Leo R. J., Khalid K. Antidepressants for chronic pain. Current Psychiatry. 2019; 18 (2):9–22. [Google Scholar]

69. Knadler M. P., Lobo E., Chappell J., Bergstrom R. Duloxetine. Clinical Pharmacokinetics. 2011; 50 (5):281–294. doi: 10.2165/11539240-000000000-00000. [PubMed] [CrossRef] [Google Scholar]

70. Sangkuhl K., Stingl J. C., Turpeinen M., Altman R. B., Klein T. E. PharmGKB summary: venlafaxine pathway. Pharmacogenetics and Genomics. 2014; 24 (1):62–72. doi: 10.1097/FPC.0000000000000003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

71. Shams M. E. E., Arneth B., Hiemke C., et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. Journal of Clinical Pharmacy and Therapeutics. 2006; 31 (5):493–502. doi: 10.1111/j.1365-2710.2006.00763.x. [PubMed] [CrossRef] [Google Scholar]

72. Veefkind A. H., Haffmans P. M. J., Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Therapeutic Drug Monitoring. 2000; 22 (2):202–208. doi: 10.1097/00007691-200004000-00011. [PubMed] [CrossRef] [Google Scholar]

73. Wijnen P. A. H. M., Limantoro I., Drent M., Bekers O., Kuijpers P. M. J. C., Koek G. H. Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity. Annals of Clinical Biochemistry. 2009; 46 (6):527–530. doi: 10.1258/acb.2009.009003. [PubMed] [CrossRef] [Google Scholar]

74. Jornil J., Nielsen T. S., Rosendal I., et al. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Forensic Science International. 2013; 226 (1-3):e26–e31. doi: 10.1016/j.forsciint.2012.12.020. [PubMed] [CrossRef] [Google Scholar]

75. Vinetti M., Haufroid V., Capron A., Classen J. F., Marchandise S., Hantson P. Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms. Clinical Toxicology. 2011; 49 (9):865–869. doi: 10.3109/15563650.2011.626421. [PubMed] [CrossRef] [Google Scholar]

76. Hicks J. K., Sangkuhl K., Swen J. J., et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clinical Pharmacology and Therapeutics. 2017; 102 (1):37–44. doi: 10.1002/cpt.597. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

See also  CBD Oil Male Enhancement

77. Zheng Y., Chen X., Benet L. Z. Reliability of in vitro and in vivo methods for predicting the effect of P-glycoprotein on the delivery of antidepressants to the brain. Clinical Pharmacokinetics. 2016; 55 (2):143–167. doi: 10.1007/s40262-015-0310-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

78. Rottmann C. N. SSRIs and the syndrome of inappropriate antidiuretic hormone secretion. The American Journal of Nursing. 2007; 107 (1):51–58. doi: 10.1097/00000446-200701000-00022. [PubMed] [CrossRef] [Google Scholar]

79. Roxanas M., Hibbert E., Field M. Venlafaxine hyponatraemia: incidence, mechanism and management. The Australian and New Zealand Journal of Psychiatry. 2007; 41 (5):411–418. doi: 10.1080/00048670701261202. [PubMed] [CrossRef] [Google Scholar]

80. Yoshida K., Aburakawa Y., Suzuki Y., Kuroda K., Kimura T. Acute hyponatremia resulting from duloxetine-induced syndrome of inappropriate antidiuretic hormone secretion. Internal Medicine. 2019; 58 (13):1939–1942. doi: 10.2169/internalmedicine.2346-18. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

81. de Abajo F. J. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs & Aging. 2011; 28 (5):345–367. doi: 10.2165/11589340-000000000-00000. [PubMed] [CrossRef] [Google Scholar]

82. Hackam D. G., Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 2012; 79 (18):1862–1865. doi: 10.1212/WNL.0b013e318271f848. [PubMed] [CrossRef] [Google Scholar]

83. Hougardy D. M. C., Egberts T. C. G., van der Graaf F., Brenninkmeijer V. J., Derijks L. J. J. Serotonin transporter polymorphism and bleeding time during SSRI therapy. British Journal of Clinical Pharmacology. 2008; 65 (5):761–766. doi: 10.1111/j.1365-2125.2008.03098.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

84. Jiang H. Y., Chen H. Z., Hu X. J., et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clinical Gastroenterology and Hepatology. 2015; 13 (1):42–50.e3. doi: 10.1016/j.cgh.2014.06.021. [PubMed] [CrossRef] [Google Scholar]

85. Letsas K., Korantzopoulos P., Pappas L., Evangelou D., Efremidis M., Kardaras F. QT interval prolongation associated with venlafaxine administration. International Journal of Cardiology. 2006; 109 (1):116–117. doi: 10.1016/j.ijcard.2005.03.065. [PubMed] [CrossRef] [Google Scholar]

86. Yekehtaz H., Farokhnia M., Akhondzadeh S. Cardiovascular considerations in antidepressant therapy: an evidence-based review. The Journal of Tehran Heart Center. 2013; 8 (4):169–176. [PMC free article] [PubMed] [Google Scholar]

87. Sidhu H. S., Sadhotra A. Current status of the new antiepileptic drugs in chronic pain. Frontiers in Pharmacology. 2016; 7 :p. 276. doi: 10.3389/fphar.2016.00276. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

88. Goodyear-Smith F., Halliwell J. Anticonvulsants for neuropathic pain: gaps in the evidence. The Clinical Journal of Pain. 2009; 25 (6):528–536. doi: 10.1097/AJP.0b013e318197d4cc. [PubMed] [CrossRef] [Google Scholar]

89. Bockbrader H. N., Wesche D., Miller R., Chapel S., Janiczek N., Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clinical Pharmacokinetics. 2010; 49 (10):661–669. doi: 10.2165/11536200-000000000-00000. [PubMed] [CrossRef] [Google Scholar]

90. Mukae T., Fujita W., Ueda H. P-glycoprotein inhibitors improve effective dose and time of pregabalin to inhibit intermittent cold stress-induced central pain. Journal of Pharmacological Sciences. 2016; 131 (1):64–67. doi: 10.1016/j.jphs.2016.01.002. [PubMed] [CrossRef] [Google Scholar]

91. Patsalos P. N., Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. The Lancet Neurology. 2003; 2 (6):347–356. doi: 10.1016/S1474-4422(03)00409-5. [PubMed] [CrossRef] [Google Scholar]

92. Gill D., Derry S., Wiffen P. J., Moore R. A. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews. 2011; 2011 (10, article CD009183) doi: 10.1002/14651858.CD009183.pub2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

93. Siemes H., Nau H., Schultze K., et al. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia. 1993; 34 (2):332–346. doi: 10.1111/j.1528-1157.1993.tb02419.x. [PubMed] [CrossRef] [Google Scholar]

94. Ghodke-Puranik Y., Thorn C. F., Lamba J. K., et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenetics and Genomics. 2013; 23 (4):236–241. doi: 10.1097/FPC.0b013e32835ea0b2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

95. Ethell B. T., Anderson G. D., Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochemical Pharmacology. 2003; 65 (9):1441–1449. doi: 10.1016/S0006-2952(03)00076-5. [PubMed] [CrossRef] [Google Scholar]

96. Ohtani Y., Endo F., Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. The Journal of Pediatrics. 1982; 101 (5):782–785. doi: 10.1016/S0022-3476(82)80320-X. [PubMed] [CrossRef] [Google Scholar]

97. Vázquez M., Fagiolino P., Mariño E. L. Concentration-dependent mechanisms of adverse drug reactions in epilepsy. Current Pharmaceutical Design. 2013; 19 (38):6802–6808. doi: 10.2174/1381612811319380012. [PubMed] [CrossRef] [Google Scholar]

98. Vázquez M., Fagiolino P., Maldonado C., et al. Hyperammonemia associated with valproic acid concentrations. BioMed Research International. 2014; 2014 :7. doi: 10.1155/2014/217269. 217269 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

99. Maldonado C., Guevara N., Queijo C., González R., Fagiolino P., Vázquez M. Carnitine and/or acetylcarnitine deficiency as a cause of higher levels of ammonia. BioMed Research International. 2016; 2016 :8. doi: 10.1155/2016/2920108. 2920108 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

100. Ewing L. E., Skinner C. M., Quick C. M., et al. Hepatotoxicity of a cannabidiol-rich cannabis extract in the mouse model. Molecules. 2019; 24 (9, article 1694) doi: 10.3390/molecules24091694. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

101. Devinsky O., Cross J. H., Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. The New England Journal of Medicine. 2017; 377 (7):699–700. [PubMed] [Google Scholar]

102. Devinsky O., Patel A. D., Cross J. H., et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. The New England Journal of Medicine. 2018; 378 (20):1888–1897. doi: 10.1056/NEJMoa1714631. [PubMed] [CrossRef] [Google Scholar]

103. Thiele E. A., Marsh E. D., French J. A., et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018; 391 (10125):1085–1096. doi: 10.1016/S0140-6736(18)30136-3. [PubMed] [CrossRef] [Google Scholar]

104. Baltes S., Fedrowitz M., Tortós C. L., Potschka H., Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. The Journal of Pharmacology and Experimental Therapeutics. 2006; 320 (1):331–343. doi: 10.1124/jpet.106.102491. [PubMed] [CrossRef] [Google Scholar]

105. Wiffen P. J., Derry S., Moore R. A. Lamotrigine for acute and chronic pain. Cochrane Database of Systematic Reviews. 2011; 16 (2, article CD006044) doi: 10.1002/14651858. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

106. Buch D., Chabriat H. Lamotrigine in the prevention of migraine with aura: a narrative review. Headache. 2019; 59 (8):1187–1197. doi: 10.1111/head.13615. [PubMed] [CrossRef] [Google Scholar]

107. Rowland A., Elliot D. J., Williams J. A., Mackenzie P. I., Dickinson R. G., Miners J. O. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metabolism and Disposition. 2006; 34 (6):1055–1062. doi: 10.1124/dmd.106.009340. [PubMed] [CrossRef] [Google Scholar]

108. Maggs J. L., Naisbitt D. J., Tettey J. N. A., Pirmohamed M., Park B. K. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chemical Research in Toxicology. 2000; 13 (11):1075–1081. doi: 10.1021/tx0000825. [PubMed] [CrossRef] [Google Scholar]

109. Naisbitt D. J. Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology. 2004; 194 (3):179–196. doi: 10.1016/j.tox.2003.09.004. [PubMed] [CrossRef] [Google Scholar]

110. Wang X. Q., Lv B., Wang H. F., et al. Lamotrigine-induced severe cutaneous adverse reaction: update data from 1999–2014. Journal of Clinical Neuroscience. 2015; 22 (6):1005–1011. doi: 10.1016/j.jocn.2015.01.016. [PubMed] [CrossRef] [Google Scholar]

111. Lalic M., Cvejic J., Popovic J., et al. Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. European Journal of Drug Metabolism and Pharmacokinetics. 2009; 34 (2):93–99. doi: 10.1007/BF03191157. [PubMed] [CrossRef] [Google Scholar]

112. Vázquez M., Maldonado C., Guevara N., et al. Lamotrigine-Valproic Acid Interaction Leading to Stevens–Johnson Syndrome. Case Reports in Medicine. 2018; 2018 :5. doi: 10.1155/2018/5371854. 5371854 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

113. Yalcin B., Karaduman A. Stevens–Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. Journal of the American Academy of Dermatology. 2012; 43 (5):703–706. [PubMed] [Google Scholar]

114. Johannessen Landmark C., Brandl U. Pharmacology and drug interactions of cannabinoids. Epileptic Disorders. 2020; 22 (1):S16–S22. [PubMed] [Google Scholar]

115. Römermann K., Helmer R., Löscher W. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2) Neuropharmacology. 2015; 93 :7–14. doi: 10.1016/j.neuropharm.2015.01.015. [PubMed] [CrossRef] [Google Scholar]

Community Forum Archive

My son had one seizure at 17 years old. He has not been diagnosed with epilepsy, but he did have an abnormal EEG that showed “slowing” so he was put on meds. After a few months on Keppra he became very depressed and moody. We changed to Lamotrigine, and although he has been seizure free for 2+ years now, he is increasingly depressed, irritable, has mood swings, and his grades in school are going down. He was always an excellent student and happy person, and now school and life in general are a struggle for him. He doesn’t even enjoy being with friends like he used to. We tried adding an antidepressant , but he didn’t like it so he stopped after a few weeks. His doctor said he could try going off Lamotrigine b/c he has been seizure free 2+ years, but we are nervous about more seizures starting at college, and also the side effects (depression, etc..) of stopping lamotrigine. What meds have others tried, other than Keppra and Lamotrigine, to control seizures and help with depressive symptoms? Has anyone gone off medication and onto CBD oil with success? Do any neurologists prescribe CBD? Our neurologist will not prescribe CBD Oil but has patients who take it. Could CBD help with lamotrigine withdrawl? Thank you everyone for listening, any advice is appreciated.

Comments

there are about 60+ meds that
Submitted by just_joe on Tue, 2017-10-24 – 17:03

there are about 60+ meds that are created to control seizures.Now you need to relax and do some research before thinking of or wanting medications. If the neurologist wants to take your son off meds because he has gone 2 years without a seizure then you should understand that he would wean your son off meds. By weaning his off slowly then he would know what dosage he needs to be at IF YOUR SON HAD A SEIZURE. There have been many people that had epilepsy and seizures that after 2 years they were taken off all meds. There have been others (my cousin was one) that was weaned off and had one. When that happened the neurologist raised the dosage to the last dosage the person had been on that kept her from having seizures. My cousin stopped having seizures but her dosage was very low. she drove and didn’t have seizures but took her meds. I know of others that never take seizure medications. CBD oil has been used for many different things. His neurologist can give you more information on it then I can. Understand too that It is still illegal in some states.

there are about 60+ meds that are created to control seizures.Now you need to relax and do some research before thinking of or wanting medications. If the neurologist wants to take your son off meds because he has gone 2 years without a seizure then you should understand that he would wean your son off meds. By weaning his off slowly then he would know what dosage he needs to be at IF YOUR SON HAD A SEIZURE. There have been many people that had epilepsy and seizures that after 2 years they were taken off all meds. There have been others (my cousin was one) that was weaned off and had one. When that happened the neurologist raised the dosage to the last dosage the person had been on that kept her from having seizures. My cousin stopped having seizures but her dosage was very low. she drove and didn’t have seizures but took her meds. I know of others that never take seizure medications. CBD oil has been used for many different things. His neurologist can give you more information on it then I can. Understand too that It is still illegal in some states.

there are about 60+ meds that are created to control seizures.Now you need to relax and do some research before thinking of or wanting medications. If the neurologist wants to take your son off meds because he has gone 2 years without a seizure then you should understand that he would wean your son off meds. By weaning his off slowly then he would know what dosage he needs to be at IF YOUR SON HAD A SEIZURE. There have been many people that had epilepsy and seizures that after 2 years they were taken off all meds. There have been others (my cousin was one) that was weaned off and had one. When that happened the neurologist raised the dosage to the last dosage the person had been on that kept her from having seizures. My cousin stopped having seizures but her dosage was very low. she drove and didn’t have seizures but took her meds. I know of others that never take seizure medications. CBD oil has been used for many different things. His neurologist can give you more information on it then I can. Understand too that It is still illegal in some states.

Thank you Joe. We talked to
Submitted by ChicagoMom on Wed, 2017-10-25 – 11:09

Thank you Joe. We talked to his doctor and the weaning off lamotrigine will take a month I guess, going down 50mg per week. I hope we can go med free now, I guess we wont really know until we try. He has had a lot of problems on the two medications, depression, lack of concentration, grades going down in college, etc.. It’s so frustrating. Thank you for responding.

Thank you Joe. We talked to his doctor and the weaning off lamotrigine will take a month I guess, going down 50mg per week. I hope we can go med free now, I guess we wont really know until we try. He has had a lot of problems on the two medications, depression, lack of concentration, grades going down in college, etc.. It’s so frustrating. Thank you for responding.

Thank you Joe. We talked to his doctor and the weaning off lamotrigine will take a month I guess, going down 50mg per week. I hope we can go med free now, I guess we wont really know until we try. He has had a lot of problems on the two medications, depression, lack of concentration, grades going down in college, etc.. It’s so frustrating. Thank you for responding.

no problem I had issues now
Submitted by just_joe on Thu, 2017-10-26 – 17:04

no problem I had issues now and then but I also learned how to do things that relaxed me which got rid of the stress. I tore things apart and put them back together.

no problem I had issues now and then but I also learned how to do things that relaxed me which got rid of the stress. I tore things apart and put them back together.

no problem I had issues now and then but I also learned how to do things that relaxed me which got rid of the stress. I tore things apart and put them back together.

Have you taken your son to an
Submitted by RTLEmum on Tue, 2017-10-31 – 14:16

Have you taken your son to an epileptologist and psychiatrist? Has he been seen in an epilepsy center and gotten an MRI? It seems that he is having symptoms without a clear diagnosis of epilepsy. I would want a few more medical opinions to rule out different kinds of epilepsy and more information on whether he is suffering mood swings or depression or side effects.

Have you taken your son to an epileptologist and psychiatrist? Has he been seen in an epilepsy center and gotten an MRI? It seems that he is having symptoms without a clear diagnosis of epilepsy. I would want a few more medical opinions to rule out different kinds of epilepsy and more information on whether he is suffering mood swings or depression or side effects.

Have you taken your son to an epileptologist and psychiatrist? Has he been seen in an epilepsy center and gotten an MRI? It seems that he is having symptoms without a clear diagnosis of epilepsy. I would want a few more medical opinions to rule out different kinds of epilepsy and more information on whether he is suffering mood swings or depression or side effects.

Sorry for typos. wrote this
Submitted by Concerned Mom_5a1c0f14ce9d4 on Mon, 2017-11-27 – 08:14

Sorry for typos. wrote this fast on my phone.

I was having up to four
Submitted by LaGallina on Fri, 2017-12-29 – 18:22

I was having up to four seizures a day without an success with seizure meds. I do the MAD ( modified Atkins diet, like the ketogenic diet but a lot easier) I take a high CBD oil/ low THC oil three times a day. The CBD oil didn’t work alone for me but it did take the edge off my Aura, reduced my twitching and I recovered better. The thing is once I ran out of the CBD oil but was sure I would be fine for one day without it and I was wrong! I started having seizures first thing the next day. Same with the diet and the THC. I have to be doing all three for it to work. I wish you the best for your son!

I was having up to four seizures a day without an success with seizure meds. I do the MAD ( modified Atkins diet, like the ketogenic diet but a lot easier) I take a high CBD oil/ low THC oil three times a day. The CBD oil didn’t work alone for me but it did take the edge off my Aura, reduced my twitching and I recovered better. The thing is once I ran out of the CBD oil but was sure I would be fine for one day without it and I was wrong! I started having seizures first thing the next day. Same with the diet and the THC. I have to be doing all three for it to work. I wish you the best for your son!

I was having up to four seizures a day without an success with seizure meds. I do the MAD ( modified Atkins diet, like the ketogenic diet but a lot easier) I take a high CBD oil/ low THC oil three times a day. The CBD oil didn’t work alone for me but it did take the edge off my Aura, reduced my twitching and I recovered better. The thing is once I ran out of the CBD oil but was sure I would be fine for one day without it and I was wrong! I started having seizures first thing the next day. Same with the diet and the THC. I have to be doing all three for it to work. I wish you the best for your son!

Drug Interaction With Cbd Oil A Lamotrigine Cbd User Guide – Global Clubfoot Initiative

Nanotechnology Cbd cbd places by me, drug interaction with cbd oil a lamotrigine Cbd Pain Relief Zebra Cbd Oil.

Shaoyun put the workbook in Xiaopang s seat, then stretched his head to key life cbd gummies look at Vanilla s math problem, Vanilla moved the workbook in front of Shaoyun, but he didn t.

When I got home from school, it was completely dark, and in the cold wind, cbd places by me What Is A Good Cbd Oil my mother stood at the door waiting for Shaoyun.

But Ye Fan really can t wait any longer In the end, there was really no other way, Ye Fan drug interaction with cbd oil a lamotrigine liberty cbd gummies third party tested could only use his trump card.

She always wanted to finish reading it, but she had no chance.

During the process of the falling stars bending, he suddenly laughed.

Everyone s eyes were fixed on Looking in one drug interaction with cbd oil a lamotrigine direction.

The frightened pigs fled to avoid them, and fought back from time to time.

It was Shaoyun s quick jump, but he still didn t dodge, bang a sound hit Shaoyun.

hehe Qian Honghong looked at Yang Liansheng s round head, and said that as much as she hated it, she just wanted to explain it, but it drug interaction with cbd oil a lamotrigine was wrong to think about it, why should I explain so cbd oil for e cig greensboro nc much to him.

See also  CBD Oil Wholesale Uk

Old monsters like them who have lived for so many years should not back down.

Jingru and Shaoyun came to the front of the wooden fence courtyard, drug interaction with cbd oil a lamotrigine Cbd Oil And Bleeding Concerns and from a distance they drug interaction with cbd oil a lamotrigine heard the old man humming a big drum in Cbd Dosage For Liver drug interaction with cbd oil a lamotrigine the vegetable field in front of the honey b cbd reviews courtyard, digging the vegetable garden in the early morning, Jingru shouted from drug interaction with cbd oil a lamotrigine a distance Grandpa, digging vegetable fields so early, I brought my classmates to see you drug interaction with cbd oil a lamotrigine and Cbd Oil Amazon cbd places by me ask you something.

After all, she doesn t have to leave the house to marry her Cbd Oil Amazon cbd places by me brother in law, and drug interaction with cbd oil a lamotrigine her daughter will not be looked upon differently.

The water and light drug interaction with cbd oil a lamotrigine came out from the ground and quickly converged.

After looking around for a while, there was no one there.

Old man. Li Tianlan shouted, his voice hoarse.

naked, obvious, close, but far away But not all the top body techniques in the dark drug interaction with cbd oil a lamotrigine world belong to the Li family.

Like a plan agreed in advance. It s like a temporary rescue.

Ye Fan then pulled out the Vulcan Sword, .

how much cbd oil should i take for lupus

and his momentum was as fierce drug interaction with cbd oil a lamotrigine Cbd Oil And Bleeding Concerns as a tiger descending the mountain.

The field is spreading like crazy. Nine feet of red dust three inches of human world.

It cbd places by me What Is A Good Cbd Oil s really good and strong, it really makes Cbd Weightloss drug interaction with cbd oil a lamotrigine us feel relieved.

Like the teacher Global Clubfoot Initiative drug interaction with cbd oil a lamotrigine who didn drug interaction with cbd oil a lamotrigine t show up, Global Clubfoot Initiative drug interaction with cbd oil a lamotrigine there were students in the back row, Gao Dazhuang.

Jade Rabbit too, beautiful longevity is synonymous with loneliness and old age.

This time, I just happened to try drug interaction with cbd oil a lamotrigine my dark avenue.

The more bloated and chaotic, the final collapse.

Disappeared from sight It was almost noon, Shaoyun went to the hospital and felt that he was cost of cbd gummies to quit smoking dying of hunger.

What happened to Cbd Weightloss drug interaction with cbd oil a lamotrigine her today, Shaoyun felt very embarrassed, neither standing nor walking, nor asking too much.

Erdanzi and Shaoyun, regardless of the scorching weather and the wetness of sweat, worked which is more of a blood thinner lexapro or cbd oil hard to harvest.

So it is more than enough to face these puppets.

Because for Ye Fan, time is money now, and he really can t wait for a moment.

Not to mention those four people, even if the chief elders and masters under his command were to face Ye Fan, they would probably only feel a highline wellness cbd night gummies deep sense of powerlessness.

Those disciples with a lower realm were all shocked at this eagle hemp cbd gummies shark tank reviews time.

Fortunately, the teeth and face were not knocked out, otherwise the teeth would cbd places by me What Is A Good Cbd Oil have to be knocked out.

With his age, his strength must have Cbd Dosage For Liver drug interaction with cbd oil a lamotrigine regressed at this time.

The dragon will look up and see cbd and drug test the dragon disarm Boom Late at night in Eastern Europe.

In the cadence of the teacher, the Cbd Oil Amazon cbd places by me students raised their ears nervously, listening to the names and scores read out The first place is Shaoyun, with a full score of 120 points, the second place is making cbd gummies with isolate drug interaction with cbd oil a lamotrigine Ji Xiaoqing with 108 drug interaction with cbd oil a lamotrigine points, and the third place is.

Jingru, we 25mg thc free cbd gummies drug interaction with cbd oil a lamotrigine don t want to now, study hard. Well, you re right.

I didn t expect him to return to Cbd Dosage For Liver drug interaction with cbd oil a lamotrigine the city ahead of time, leaving her alone in this distant foreign land.

Stop it. But when I waited and waited, I didn t does cbd show on drug test ca drug interaction with cbd oil a lamotrigine Cbd Oil And Bleeding Concerns see Principal Pan appearing.

After all, we don t have any support. When something really happens, the trouble will be a little bigger.

the lake is rippling with water and grass. The fish swim on the shallow bottom and play with the wind, and the beach is boundless.

After the battle just now, although our losses were a little heavy, the Black Wind King should have also been injured.

These are small things, come with me. Okay After Lin Mu really took Ye Fan to visit Jinghu Villa, Ye Fan learned the true strength of this sect.

Qin Weibai did cbd places by me What Is A Good Cbd Oil what he wanted. buy weed edibles online The chess skills of the two are not low, and the outcome is even with each other, so in the past few days, drug interaction with cbd oil a lamotrigine in their spare time, the is it okay to take cbd oil every day two have played a lot of chess.

Lin Fengting smiled wryly again. Qin Weibai couldn t even tell how she felt about the Li family.

Generally, when a boy breaks drug interaction with cbd oil a lamotrigine up with a girl, he Cbd Dosage For Liver drug interaction with cbd oil a lamotrigine can take the drug interaction with cbd oil a lamotrigine opportunity to shake hands tightly, feel the strangeness of the other party s sweaty palms, and feel a lot of Cbd Weightloss drug interaction with cbd oil a lamotrigine masturbation in his heart.

So on the phone, in the face of drug interaction with cbd oil a lamotrigine Wang Tianzong, who is always in awe and has estrangement, Chen Qingluan s tone has become a little excited Your Majesty, this is an opportunity, why don t we push it together Cbd Oil Amazon cbd places by me with Kunlun dragonfly coffee cup City No drug interaction with cbd oil a lamotrigine hurry.

No, no, grandpa, go back first, I ll wait here for you to come back.

More experts from Reiki City in the rear also rushed over.

Yes, we have drug interaction with cbd oil a lamotrigine the leader of the Black Wind King, and it s only drug interaction with cbd oil a lamotrigine a matter of time before they are wiped out.

He chased into the pig house, closed the gate, and waved the windy broom to beat the big pig.

How often should you take cbd oil?

know that these medicinal herbs are definitely treasures when they are placed outside, but now they are like those in drug interaction with cbd oil a lamotrigine the bad street who don t want money.

This is the way of Qingfeng practiced by Zhenren Qingfeng, which can drug interaction with cbd oil a lamotrigine purify people s minds.

And they are all from the elite of the frontier army.

Or maybe he didn t drug interaction with cbd oil a lamotrigine care about this time at cbd oil gummy worms all.

I don t know if we are both in the early stage of the mixed Global Clubfoot Initiative drug interaction with cbd oil a lamotrigine magic mirror, can he beat me A strange smile drug interaction with cbd oil a lamotrigine appeared on the corner of the Evil God of Fire cbd gummies what do you use it for s mouth.

Everyone is a little flustered, so cbd places by me What Is A Good Cbd Oil everyone forms a line and walks slowly towards the shore Oops drug interaction with cbd oil a lamotrigine My mother, what did you step on Yang Liansheng shouted, but it turned out that Yang Yuqi was a dead frog.

The two of them went about their business silently, I ll go back first, I have a few more things to drug interaction with cbd oil a lamotrigine Cbd Oil And Bleeding Concerns do.

Ye Fan watched this scene, and the corners of his mouth rose slightly, this was what he expected.

Hehe, you want to know who I am, right But you may not have this qualification.

She never imagined drug interaction with cbd oil a lamotrigine that she would drug interaction with cbd oil a lamotrigine encounter such a thing by borrowing a dustpan.

What the hell is going on here Why is it I ve already done my best, whether it s in the accumulation of resources or in the battle drug interaction with cbd oil a lamotrigine with people, why can t I break through After staying for such a long time, are you going to be trapped in the Cbd Weightloss drug interaction with cbd oil a lamotrigine early stage of the Demon Realm for the rest of your life I don t accept it I really don t accept it drug interaction with cbd oil a lamotrigine Ye Fan roared in the sky, and his whole person was extremely unwilling.

Yang Liansheng and I hid it here. Somehow, drug interaction with cbd oil a lamotrigine this little .

cbd oil chattanooga tn

bird was kokopelli 1000mg full spectrum high potency organic hemp cbd extract oil yhc content originally a secret for Cbd Oil Amazon cbd places by me her and Yang Liansheng, but she was .

cbd oil for fatigue

willing to let it go.

Around the whole school, a kanaste cbd oil circle of tall poplar trees are planted.

Because in the eyes Cbd Dosage For Liver drug interaction with cbd oil a lamotrigine .

can cbd oil cause heart palpitations

of these disciples of the evil faction, drug interaction with cbd oil a lamotrigine Lin Mu is completely demon like, even Cbd Dosage For Liver drug interaction with cbd oil a lamotrigine more differences in cbd oil threatening than those bigwigs.

Chen Qingluan Cbd Weightloss drug interaction with cbd oil a lamotrigine s task was to keep an eye on Li Tianlan.

But who can say such things clearly If it s really not what you think at that time, then it will be a big trouble.

They soon became best friends. Liang Shanshan s academic performance is not very good, she likes to play, and she likes to play football with Cbd Dosage For Liver drug interaction with cbd oil a lamotrigine a good physique.

Amidst the hazy luster, Li Tianlan s figure appeared most clearly within the Jiuzhang Hongchen.

Jingru used Qinghua s tone to send a message to ask the militia battalion commander to make an appointment.

He took out the book and stuffed Qian Honghong a small bag of fried peanuts at the same time.

Woven reed mats wear down fingers and hurt legs.

When Shaoyun calmed cbd oil and clearance down, the test questions drug interaction with cbd oil a lamotrigine were .

cbd oil color change

completed quickly, and he quickly checked twice to confirm drug interaction with cbd oil a lamotrigine that there was hemp meaning in spanish no content to be changed, Teacher, drug interaction with cbd oil a lamotrigine I want to hand in the paper Shaoyun decisively handed in drug interaction with cbd oil a lamotrigine the test paper, and there Cbd Weightloss drug interaction with cbd oil a lamotrigine Cbd Dosage For Liver drug interaction with cbd oil a lamotrigine are still more than a dozen before get out of class ends.

The warm atmosphere is still in my mind. Vanilla saw the change in Jingru s expression and clicked until she did not continue to speak, so as not to reveal her true thoughts, drug interaction with cbd oil a lamotrigine knowing that her words had provoked Jingru s hatred for Cbd Oil Amazon cbd places by me Qian Honghong, and quietly concealed her feelings towards Qian Hong.

I saw golden fruits and flowers blooming on the green leaves.

For the following The elders and the high level happy King of the Black Wind just smiled slightly.

When the second daring woke up, the grandmother hugged the grandson and cried with joy.

You re a big head, Huimin, I see your head has become round again, haha Jingru shouted happily when buy cbd with thc gummies she saw her classmates.

Shaoyun and Cbd Weightloss drug interaction with cbd oil a lamotrigine Jingru talked about foreign literary novels, poems and songs, and the background of the writing era.

The occurrence of the broken head, instead, narrowed the friendship between Jingru and Shaoyun, making Huzi even less favorable in Jingru s heart.

It is one drug interaction with cbd oil a lamotrigine of the best seats in the classroom. In the future, if the seats are ranked drug interaction with cbd oil a lamotrigine by grades, the six desks in the middle of the third to sixth rows will be the seats Cbd Dosage For Liver drug interaction with cbd oil a lamotrigine for competition.

The xanax vs marijuana jet black dagger in his hand waved from a distance of 100 meters.

Because Ye Fanke and Lin Mu are about the same age, Lin Mu is in the middle stage of Tianxian, and he is drug interaction with cbd oil a lamotrigine already a great arrogance among his disciples.

With your current state, you can t lead the way, and all the avenues are nothing in front of all the strengths.

Jingru greeted Shaoyun and Erdanzi and walked to the village.

Classmate Yang Liansheng, you Teacher Yang Yu was stunned.

It is drug interaction with cbd oil a lamotrigine estimated that Qingfeng Zhenren has already received the drug interaction with cbd oil a lamotrigine news.

Therefore, the lineup of Tianyi drug interaction with cbd oil a lamotrigine Pavilion to attend the meeting at this time is also extremely luxurious.

This Cbd Weightloss drug interaction with cbd oil a lamotrigine is the respect of Ye Fan and drug interaction with cbd oil a lamotrigine Lin Mu to Liu Dazui and others, and then the two turned Global Clubfoot Initiative drug interaction with cbd oil a lamotrigine to leave.

We will definitely take action at this critical moment and completely destroy them.

The wild thunder light completely enveloped Li Tianlan in an instant.

Two young boys and girls walking in such illusory and cold snow, their hearts cbd gummies california torrance can t help beating.

Shaoyun drug interaction with cbd oil a lamotrigine s mother looked at Uncle Zhang who was far away, still standing in front of the yard door in a daze, and does cbd oil help with alcohol cravings she kept nagging, I passed the entrance examination, I passed the entrance examination, the baby is really worry free.

As soon cbd places by me What Is A Good Cbd Oil as there was movement in this drug interaction with cbd oil a lamotrigine wing, a loud voice came from the other wing Cbd Weightloss drug interaction with cbd oil a lamotrigine The child is awake.

Zhong roared and rushed out of the Asuka base. Money is a kind of power.

The four of them walked around the cultural center and Cbd Dosage For Liver drug interaction with cbd oil a lamotrigine read a book in the reading room drug interaction with cbd oil a lamotrigine for a while.

Lin Mu was also attentively drug interaction with cbd oil a lamotrigine Cbd Store Online explaining Jinghu Villa to Ye Fan at this time.

It s so powerful that it can break up the battle of the four of us with one move.

You can see through the light, and the thick eyebrows and drug interaction with cbd oil a lamotrigine nose and face are squeezed together.

I want to know the real reason from his mouth. After recovering a little bit of Yun Guantian, drug interaction with cbd oil a lamotrigine without any delay, he drug interaction with cbd oil a lamotrigine cbd places by me just sat up cross legged and meditated.

cbd oil el paso

Qian Honghong was most worried about drug interaction with cbd oil a lamotrigine Cbd Oil And Bleeding Concerns was math scores.

In Central Continent, there are the Beihai Wang Family and the Kunlun City.

Jiang Qiannian couldn t do this, but he was able to narrow the field to about 60 meters.

In fact, this is no wonder, because among the three thousand avenues, the time and space avenues are the most difficult to comprehend.

Mother was silent for a while, I ll prepare it for you, you does cbd oil increase heart rate go to bed first.

The fighting spirit climbed to its peak. Strength, speed, will, sword intent, fist intent are completely sublimated.

Shaoyun carefully balanced the plane and threw it out, which cbd places by me What Is A Good Cbd Oil was still higher than Jingru s plane.

So be sure to do all the preparations this time.

I won t be back until school starts. Mom and Dad are both at work, so fresh leaf cbd oil review they can t take care of me.

is hemp oil cbd oil

it was windy or rainy, sunny or cloudy, she always carried it with her.

When Shaoyun heard this, he begged Jingru to take him to see the uncle who could tell stories.

Just as they were about to go over drug interaction with cbd oil a lamotrigine to take a look, they heard an old gentleman who was looking for a fortune teller in front of him stopped Shao Yun and Yang Liansheng Two little brothers, look at your palms, drug interaction with cbd oil a lamotrigine you can count.

The tiger behind was a little anxious, and could Global Clubfoot Initiative drug interaction with cbd oil a lamotrigine not wait to stand up and read Shaoyun s papers.

Ye Fan had previous experience in frankincense oil in bath the barren world and Guangming Pavilion.

She pushed the glasses on the bridge of her nose, her eyes were close to Xiaopang Global Clubfoot Initiative drug interaction with cbd oil a lamotrigine s hand, and she said sympathetically, Ah, there is a hole Don t move, it s bleeding, I ll help you fix it.

She was about to lose this guy. Just then , only to hear someone shout Tao Dazhuang, your mother came to school to find you.

On this issue, you drug interaction with cbd oil a lamotrigine should have more common topics when you talk to God.

A vague ominous premonition came to Yang Liansheng s heart.

The rewards are often very generous. If anyone can win the first place, it will be Cbd Weightloss drug interaction with cbd oil a lamotrigine an extremely honorable thing for his cultivation and even his sect, and drug interaction with cbd oil a lamotrigine he will be able to do more with less.

The weather is getting colder and colder. When I wake up in the morning and look outside, the Global Clubfoot Initiative drug interaction with cbd oil a lamotrigine sky drug interaction with cbd oil a lamotrigine and the ground are pure white.

Shaoyun returned to Global Clubfoot Initiative drug interaction with cbd oil a lamotrigine his seat in the classroom, and as soon as he sat down, the art teacher brought the lesson plan to the door.

Today drug interaction with cbd oil a lamotrigine s game is Go. The black and white children are on the chessboard step by step, and the chess cbd drug interaction with cbd oil a lamotrigine places by me game is exquisite and grand.

How useful was this post?

Click on a star to rate it!

Average rating 3 / 5. Vote count: 1

No votes so far! Be the first to rate this post.